| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
WOBURN, Mass., November 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today re... |
| 30 Oct 2026 | 25-NSE |
| 14 Sep 2026 |
8-K: Other Events
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy plat... |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today repo... |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 |
Form 4: Luebbert Hermann, Director
Received 62,500 shares by exercise or conversion |
| 29 Jul 2026 |
Form 4: Leffler Eugene Frederick, Chief Financial Officer
Received 31,250 shares by exercise or conversion |
| 22 Jul 2026 | S-8 |
| 22 Jul 2026 | 10-K/A |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Biofrontera Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and th... |
| 14 May 2026 | 10-Q |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported ... |
| 30 Apr 2026 | Proxy statement: annual meeting on June 11, 2026 |
| 19 Mar 2026 | 10-K |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Woburn, MA (March 19, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported... |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris |
| 06 Mar 2026 |
Form 4: Luebbert Hermann, Director
Granted 125,000 Restricted Stock Units · Granted 125,000 Employee stock option (right to buy) · Received 137,500 shares by exercise or conversion |
Loading...